Introduction
============

The elderly are usually fragile and more susceptible to drug-related problems as a result of multimorbidity, polypharmacy, and physiological changes that affect the pharmacokinetics and pharmacodynamics of drugs.[@b1-cia-14-535] Therefore, this population is more prone to using medications that can be considered inappropriate.

A potentially inappropriate medication (PIM) is any medication used by a patient that could introduce a significant risk of an adverse drug reaction (ADR), in particular when there is an equally or more effective alternative with lower risk available. In the elderly, ADRs can sometimes be difficult to recognize as they often present with unspecific symptoms (eg, falls, fatigue, and orthostatic hypotension). ADRs are observed 2--3 times more often in the elderly and account for 5%--17% of all hospital admissions.[@b2-cia-14-535] A systematic review has found a mean prevalence of ADRs in the elderly of 11% (95% CI: 5.1%--16.8%) and a prevalence of ADRs leading to hospitalization of 10% (95% CI: 7.2--12.8). These authors have also shown that increased comorbid complexity and increased number of medications were significantly associated with an increased risk of ADRs.[@b3-cia-14-535] It is estimated that 30%--60% could be prevented.[@b2-cia-14-535] A recent study has shown that 45.1% (95% CI: 33.1%--57.2%) of the ADRs leading to hospitalization were preventable.[@b4-cia-14-535] In the USA and Canada, the prevalence ranged between 14% and 37.0%;[@b5-cia-14-535] in Europe, the prevalence ranged between 23% and 43%.[@b6-cia-14-535] Differences found between both continents could be explained by different drug markets, different prescribing patterns, and most importantly, by the tool used to measure prevalence.[@b7-cia-14-535]

Several tools have been developed to guide prescribing, to maximize the efficacy and safety of therapy, and to minimize the consequences of using PIMs, including costs, hospitalizations, and mortality.[@b8-cia-14-535] The Beers criteria (Mark Beers, MD) was the first tool, developed in 1991, and last updated in 2019 by the American Geriatric Society.[@b9-cia-14-535],[@b10-cia-14-535] Since then, a considerable number of tools have been developed, describing not only PIMs, but also drug--drug and drug--disease interactions.[@b3-cia-14-535] Most of these tools are based on explicit criteria, ie, are normally more drug- or disease-oriented and are developed based on literature review, expert opinions, and consensus techniques.[@b3-cia-14-535]

Cardiovascular diseases (\[CVDs\] which also include cerebrovascular diseases) such as hypertension, coronary heart disease, congestive heart failure, stroke, and atrial fibrillation are prevalent among the elderly.[@b11-cia-14-535] They represent one of the leading causes of death worldwide, with 17.7 million deaths registered in 2015 (31.0% of all-cause mortality).[@b12-cia-14-535],[@b13-cia-14-535] In Europe, 3.9 million people (45.0% of all-cause mortality) have died from CVDs in 2016.[@b13-cia-14-535]

Few studies have identified PIMs in patients with CVD. A study conducted in a cardiology service showed that 20% of hospitalized patients were previously exposed to a PIM in the ambulatory setting.[@b14-cia-14-535] However, information on PIMs associated with risk of cardiovascular adverse events, especially with major adverse cardiac and cerebrovascular events (MACCE) for elderly is still scarce. Some of these medications can increase the risk of cardiovascular events or even exacerbate underlying conditions. Our previous systematic review showed that there is a restricted number of PIMs described addressing their association with the risk of cardiovascular adverse events.[@b20-cia-14-535] Some pharmacotherapeutic groups have been established to be associated with cardiovascular events such as nonsteroidal anti-inflammatory drugs (NSAIDs), antipsychotics, selective calcium channel blockers, and dopaminergic agents. Unfortunately, the prevalence of those PIMs in elderly patients is still unknown.

The primary objective of this study was to assess the prevalence of PIMs with risk of MACCE in the elderly. We then specifically aimed to study the prevalence of PIMs with risk of cardiac and cerebrovascular adverse events (CCVAEs) and to study the presence of these PIMs in patients with previous history of CVD.

Materials and methods
=====================

Study design
------------

A descriptive cross-sectional study was conducted, where a convenience sample (based on geographic criteria) of citizens living in long-term care facilities (LTCFs) in the region of Lisboa e Vale do Tejo and the region of Alentejo and independently in their own home (ambulatory) in the region of Lisboa e Vale do Tejo, Portugal were invited to participate. Citizens' information (including drug use) was collected from two LTCFs in the region of Lisboa e Vale do Tejo and two LTCFs in the other region of Alentejo. While, for individuals who live independently in their own home, citizens' information was collected from their community pharmacy.

Population and sample
---------------------

The study population (n=904) consisted of 224 residents and 680 patients from the community pharmacy and the LTCF, respectively. In the LTCF, residents were eligible if they were aged 65 or older and living in the facility until 2017. In the community pharmacy, the study population was calculated based on the minimum legal number of inhabitants per pharmacy (3,500 inhabitants) and on the percentage of elderly living in the district of Cascais in 2016 (19.6%). Moreover, individuals were included if they were aged 65 or older and had their medication history available in the pharmacy database in 2017. We excluded patients if their records were out of date, ie, if there were no sales in 2017.

Outcomes' definition and measurement
------------------------------------

Our previous study focused on a systematic review of 24 PIM-lists, where PIMs associated with CCVAEs and MACCE were identified ([Table S1](#SD1-cia-14-535){ref-type="supplementary-material"} shows the full list of those PIMs). As the primary outcome, the presence of PIMs with risk of MACCE was defined as PIMs with risk of causing stroke, transient ischemic attack, myocardial infarction, heart failure, and cardiovascular death. A secondary outcome was defined as the presence of PIMs with risk of CCVAEs including the risk of hypertension, orthostatic or postural hypotension, bradycardia, QT prolongation, and cardiac arrhythmias.

Data extraction
---------------

Data were extracted for sociodemographics (age and sex), clinical features (number of comorbidities, previous history of CVD, and the presence of dementia), and drug-related characteristics (number of medications and presence of polypharmacy). The previous history of CVD and the presence of dementia were defined according to medication used to treat CVD and dementia, respectively, as a proxy. Polypharmacy was defined as taking five or more medications.[@b15-cia-14-535] Information on comorbidities was validated by one member of the research team (JPA) and then confirmed by a physician (LHC). For the records with medical diagnosis, the validation process was performed by comparing the available medical diagnoses with the medication used. When information was insufficient to reach a consensus, data were considered missing.

Ethics and confidentiality
--------------------------

The use of patients' medical and pharmacotherapeutic records was authorized by the clinical directors of all participating institutions. To ensure anonymity, alphanumeric codes were used to identify the patients. All research was conducted following the principles of the Helsinki Declaration. Ethics approval was obtained from Comissão de Ética para a Investigação nas Áreas de Saúde Humana e Bem-Estar da Universidade de Évora (document 14017).

Data analysis
-------------

The total number of PIMs, total number of patients using PIMs, and total number of patients using PIMs with previous history of CVD were assessed. The most commonly described PIMs were analyzed and coded by pharmacotherapeutic groups, using the WHO ATC classification system.[@b15-cia-14-535]

Statistical analysis was performed using IBM SPSS v.24.0. Descriptive statistics were used, where numerical variables were expressed using central tendency and dispersion measures (either as mean and SDs, whichever was applicable) and categorical variables as absolute and relative frequencies. Bivariate statistics were used to compare both settings regarding differences in sociodemographic, clinical, and pharmacotherapeutic features. Chi-squared test and Student's *t*-test for independent samples were used, whichever was applicable considering a 95% CI. For numerical variables, normal distribution was also assessed.

The prevalence of PIMs with the risk of CCVAE or MACCE occurrence was calculated using the following formula: $$\text{Prevalence~of~PIMs} = \frac{\text{Elder~patients~presenting~one~or~more~PIIMs~with~CV~risk}}{\text{Total~number~of~older~individuals}}$$

Results
=======

Patients' characteristics
-------------------------

From the initial 904 elderly patients, 63 were excluded from the LTCF sample and 161 from the community pharmacy sample due to missing data or records which were out of date. The final sample consisted of 680 patients, in which most of them were female (n=428; 62.9%) with a mean age of 78.4±8.1 years (range: 65; 101). Patients had a mean of 3.7±1.8 comorbidities, approximately 77.0% (n=521) presented with a history of CVD, and 10.7% (n=73) also presented with dementia. The total number of medications prescribed was 5,112, with a mean number of medications taken per patient of 7.5±4.2. [Table 1](#t1-cia-14-535){ref-type="table"} describes the sample's sociodemographic and clinical features and details the differences by settings.

In LTCF, patients were older than in the ambulatory setting (85.4±6.5 vs 76.7±7.5; *P*\<0.0001). Patients in LTCFs were also more associated with a higher number of comorbidities (4.7 vs 3.5 comorbidities/patient; *P*\<0.0001) and medications used (10.4 vs 6.8 medications/patient; *P*\<0.0001) compared to ambulatory care.

PIMs with risk of CCVAEs
------------------------

After applying the PIM-list specific for CCVAEs, a total of 682 PIMs were identified from the overall sample. Most of the patients (55.2%) took one PIM with a mean number of 1.7±1.0 PIMs used per patient. The prevalence of PIMs with risk of CCVAEs was 59.4% (n=404) and 47.4% (n=322) of patients had a previous history of CVD.

The prevalence of these PIMs among the elderly in LTCFs was substantially higher when compared to the ambulatory setting (78.1% vs 54.7%; *P*\<0.0001). A similar proportion was observed for patients with a previous history of CVD (63.5% in LTCFs vs 46.6% in ambulatory setting; *P*\<0.0001). These patients were also more prone to using two PIMs when compared to patients from ambulatory setting (33.6% in LTCFs vs 19.1% in ambulatory setting; *P*=0.001). [Table 2](#t2-cia-14-535){ref-type="table"} summarizes all previously described data.

In the overall sample, the pharmacotherapeutic groups most commonly found associated with cardiovascular risk of adverse events were: non-steroidal anti-inflammatory drugs (\[NSAIDs\] n=199; 29.7%); antipsychotics (n=118; 17.6%); thyroid preparations, ie, levothyroxine (n=70; 10.4%); and antidepressants (n=57; 8.5%). Other drug classes were also found to a lower extent: peripheral vasodilators, eg, nicergoline and pentoxifylline (n=33; 4.9%), natural products, eg, gingko biloba (n=25; 3.7%), antiarrhythmics, eg, amiodarone, flecainide, and propafenone (n=19; 2.8%); and cardiac glycosides, eg, digoxin (n=18; 2.7%). [Table 3](#t3-cia-14-535){ref-type="table"} describes all the pharmacotherapeutic groups with risk of CCVAEs found in the overall sample.

NSAIDs were mostly used by patients recruited from the community pharmacy (12.7% in LTCFs vs 36.2% in ambulatory setting), as well as thyroid preparations (8.8% in LTCFs vs 11.1% in ambulatory setting). Conversely, antipsychotics (38.7% vs 9.9% in ambulatory setting), dopaminergic agents (3.3% vs 0.6% in ambulatory setting), and cardiac glycosides (6.6% vs 1.2% in ambulatory setting) were more frequently found in patients from LTCFs.

PIMs with risk of MACCE
-----------------------

From the 682 PIMs identified, more than a half (n=378) were associated with risk of MACCE. A mean number of 1.4±0.8 PIMs were used per patient, with the majority of them using between one and two PIMs (92.4%). In the overall sample, the prevalence of PIMs with risk of MACCE was 38.8% (n=264), and 29.7% (n=202) of patients also had a previous history of CVD ([Table 2](#t2-cia-14-535){ref-type="table"}).

The prevalence of these PIMs among the elderly was substantially higher in LTCFs compared to the ambulatory setting (51.8% vs 35.5%, respectively; *P*\<0.0001). A similar proportion was observed for patients with a previous history of CVD (40.1% in LTCFs vs 27.1% in ambulatory setting; *P*=0.003).

NSAIDs (n=199; 53.1%) and antipsychotics (n=118; 31.5%) were the most prevalent drug classes in the overall sample. However, antipsychotics were mostly used by patients in LTCFs, and NSAIDs by patients from the ambulatory setting. To a lower extent, antidepressants (eg, venlafaxine), selective calcium channel blockers with mainly vascular effects (eg, nifedipine) were also identified. The individual drugs most commonly found in each group were: quetiapine (n=48; 40.7%); ibuprofen (n=46; 23.1%); diclofenac (n=43; 21.6%); melperone (n=19; 16.1%); cyamemazine (n=13; 11.0%); etoricoxib (n=20; 10.0%); and naproxen (n=20; 10.0%). [Table 4](#t4-cia-14-535){ref-type="table"} summarizes all the PIMs with risk of MACCE identified in the overall sample and by setting.

No differences were found in the distribution of pharmacotherapeutic groups. In patients with previous history of CVD, 91.7% (LTCFs =22/ambulatory =24) were using nifedipine, 81.0% (17/21) venlafaxine, 77.0% (10/13) estrogen, 76.7% (69/90) antipsychotics, and 76.1% (118/155) NSAIDs.

One of the subpopulations where antipsychotics should be avoided is the demented elderly patient. From the 73 demented patients, more than half (n=39; 53.4%) were taking antipsychotics. This value was even higher if we only restricted the analysis to LTCFs: 88% (22/25). Conversely, a lower proportion of patients in primary care used antipsychotics (n=17; 35.4%). In addition, the type of antipsychotics selected also seemed to be influenced by setting, where second-generation antipsychotics were more widely found in the ambulatory setting, whilst first-generation antipsychotics were most common in LTCFs.

Discussion
==========

This study enabled the possibility of assessing the prevalence of PIMs with risk of CCVAEs and MACCE in an elderly Portuguese sample and, to the best of our knowledge this is the first study focusing on this topic in Europe. Inappropriate prescribing is more likely to occur in the elderly, since this subpopulation is generally using more medications to treat several chronic conditions. In this study, patients presented an average of 3.7±1.8 comorbidities and were taking on average 7.5±4.2 medications. The majority of these patients were taking PIMs with CCVAE risk (59.4%) and almost half of them were associated with MACCE risk. It is well-known that CVDs are frequently found in the elderly and are an important cause of morbidity and mortality in these patients. Thus, in patients with a previous history of CVD, the prevalence of PIM use was also high. A previous study focusing on the identification and quantification of PIMs with MACCE risk, using tools addressing inappropriate prescribing, was used to assess the prevalence of these medications in our sample. This list was driven by a previous systematic review that included 24 of the tools currently available (eg, Beers criteria, START/STOPP criteria, and Zhan criteria). Different studies, in different health care settings, have also investigated the prevalence of PIMs, but did not focus on a specific negative outcome. In Portugal, da Costa et al (2016) used different criteria to assess the prevalence of PIMs in elderly residents in nursing homes. They found that using Beers criteria, Beers criteria adapted to Portugal and START/ STOPP criteria, the prevalence of PIMs was 85.1%, 60.3%, and 75.4%, respectively. These patients had an average age of 84.7±6.35 years and a mean of 4.1±2.14 comorbidities.[@b16-cia-14-535] Another study, conducted by Nyborg et al (2017), showed that the prevalence of PIMs in Norwegian elderly was 43.8%, using the Norwegian General Practice Nursing Home (NORGEP-HN) criteria.[@b17-cia-14-535] In the outpatient setting, in the USA, the prevalence of PIMs was 23.3% and 16.2% using the Beers criteria and Zhan criteria, respectively.[@b18-cia-14-535]

The elderly tend to present with multiple chronic conditions, which increases the odds of using multiple medications. Many patients in this study had a previous history of CVDs and 10% also presented with dementia. The most commonly prescribed pharmacotherapeutic groups were NSAIDs and antipsychotics. NSAIDs are known to be associated with exacerbation of heart failure and to cause major cardiac events like stroke and myocardial infarction. Among NSAIDs, selective cyclooxygenase-2 (COX-II) inhibitors (eg, etoricoxib and celecoxib) are associated with an increased risk of myocardial infarction.[@b19-cia-14-535] In this study, 15.5% of patients took selective COX-II inhibitors. The 2015 Beers criteria alert for the potentially inappropriate prescribing of antipsychotics in patients with dementia. This pharmacotherapeutic group is known to be associated with an increased risk of stroke.[@b10-cia-14-535] Even though not many demented patients were found in our sample, almost 77.0% of them were taking antipsychotics. These medications were commonly used in patients in LTCFs, where more frail elderly patients can be found, and are normally used in combination with other high-risk medications for cardiovascular events, such as dopaminergic agents or antidepressants.

We assume patients in LTCFs seem to have a higher risk of MACCE occurrence because of a higher prevalence of PIMs' use, in addition, a higher prevalence of medications with higher odds of drug--drug and drug--disease interactions was found. Additionally, these elderly patients have more comorbidities and use more medications increasing the cardiovascular risk for future events. These findings suggest that more attention should be paid to tertiary care to optimize medication, by reducing the use of these drugs.

The high prevalence of PIMs with the risk of CCVAEs and MACCE may suggest that interventions targeted at medication misuse need to be further developed and implemented into practice. However, we should keep in mind that the existing criteria, in most cases, do not explicitly assess patient-related indicators (eg, weight, cardiac disturbances, and patients with high cardiovascular risk score) or drug-related indicators (eg, route of administration, dosage, and frequency of exposure). A good example is levothyroxine. This drug does not have an alternative suggested in the lists and sometimes is considered as potentially inappropriate, given the risk for cardiac arrhythmias. This is surely a drawback in practice if we consider the likelihood of a clinician basing his decisions on such lists. Perhaps more complex and tailored indicators should be developed to target high-risk patients where the PIMs identified are indeed potentially inappropriate for that specific individual. A possible example of an intervention could be the familiarization or even the inclusion of these last indicators in an information and technology strategy to foster de-prescribing during the medication review process, where full clinical and laboratory details would be embedded in the software.

Limitations
===========

This study has some limitations. First, to assess drug use in the ambulatory setting, we reported community pharmacy data which limited our ability to extract accurate information on patients' comorbidities, and consequently the capacity to judge drug--disease interactions. Second, the number of comorbidities, the previous history of CVD, and the presence of dementia were based on the analysis of the pharmacotherapeutic regimen of each patient available in the community pharmacy and LTCF. We therefore believe that comorbidities are more likely to be underreported and some misclassification bias could also be present. However, to minimize this bias, we have assessed comorbidities as a group (history of CVD or dementia), instead of using individual diagnoses from both settings. Third, we had incomplete information on all drug-related variables in both settings, which did not allow for the extraction of the frequency of exposure. Finally, although we had a good sample size, the results should only be generalized to elderly patients included in those regions (restricted to both settings) and not nationwide.

Conclusion
==========

More than half of the elderly included in our sample were using PIMs with risk of CCVAEs, and approximately 40% of those were associated with risk of MACCE. About half of patients with a previous history of CVD took PIMs. The most commonly used PIMs with risk of MACCE were NSAIDs and antipsychotics, which accounted for almost half of the total drugs assessed in this sample. Future interventions and more tailored tools for the management of drug therapy in elderly patients with CVD are of major importance.

Supplementary material
======================

###### 

Potentially inappropriate medications with risk of cardiovascular adverse events in the elderly

  ---------------------------------------------------------------------------------------------------------------------------------------
  Adverse drug reactions                                 Potentially inappropriate medications (medication classes or individual drugs)
  ------------------------------------------------------ --------------------------------------------------------------------------------
  **Major adverse cardiac and cerebrovascular events**   

  Stroke                                                 **NSAIDs \[M01A\]**\
                                                         COX-II Inhibitors \[M01AH\]\
                                                         **Antipsychotics \[N05A\]**\
                                                         Pimozide \[N05AG02\]\
                                                         **Hormones and related agents \[L02A\]**\
                                                         Estrogens \[L02AA\]\
                                                         **Selective calcium channel blockers with mainly vascular effects \[C08C\]**\
                                                         Nicardipine \[C08CA04\]\
                                                         Short-acting nifedipine \[C08CA05\]\
                                                         Long-acting nifedipine \[C08CA05\]\
                                                         **Antidepressants \[N06A\]**\
                                                         Venlafaxine \[N06AX16\]

  Myocardial infarction                                  **NSAIDs \[M01A\]**\
                                                         COX-II Inhibitors \[M01AH\]\
                                                         **Amphetamines**\
                                                         **Selective calcium channel blockers with mainly vascular effects \[C08C\]**\
                                                         Nicardipine \[C08CA04\]\
                                                         Short-acting nifedipine \[C08CA05\]\
                                                         Long-acting nifedipine \[C08CA05\]

  Sudden cardiac death                                   **Propulsives \[A03F\]**\
                                                         Domperidone (\>30 mg/d) \[A03FA03\]

  Heart failure                                          **NSAIDs \[M01A\]**\
                                                         COX-II Inhibitors \[M01AH\]\
                                                         Naproxen (long-term use) \[M01AE02\]\
                                                         Piroxicam (long-term use) \[M01AC01\]\
                                                         Oxaprozin (long-term use) \[M01AE12\]\
                                                         **Urologicals \[G04B\]**\
                                                         Sildenafil \[G04BE03\]\
                                                         Tadalafil \[G04BE08\]\
                                                         **Antiarrhythmics (Class I and III) \[C01B\]**\
                                                         Disopyramide \[C01BA03\]

  **Cardiac and cerebrovascular adverse events**         

  Hypertension                                           **NSAIDs \[M01A\]**\
                                                         Aceclofenac \[M01AB16\]\
                                                         Acemetacin \[M01AB11\]\
                                                         Celecoxib \[M01AH01\]\
                                                         Dexketoprofen \[M01AE17\]\
                                                         Diclofenac \[M01AB05\]\
                                                         Etoricoxib \[M01AH05\]\
                                                         Flurbiprofen \[M01AE09\]\
                                                         Ibuprofen \[M01AE01\]\
                                                         Indometacin \[M01AB01\]\
                                                         Ketoprofen \[M01AE03\]\
                                                         Lornoxicam \[M01AC05\]\
                                                         Mefenamic acid \[M01AG01\]\
                                                         Meloxicam \[M01AC06\]\
                                                         Nabumetone \[M01AX01\]\
                                                         Naproxen \[M01AE02\]\
                                                         Oxaprozin \[M01AE12\]\
                                                         Piroxicam \[M01AC01\]\
                                                         **Other analgesics and antipyretics \[N02B\]**\
                                                         Acetylsalicylic acid \[N02BA01\]\
                                                         **Psychostimulants \[N06B\]**\
                                                         Amphetamine \[N06BA01\]

  Heart block                                            **Antidepressants \[N06A\]**\
                                                         Amitriptyline \[N06AA09\]\
                                                         Amoxapine \[N06AA17\]\
                                                         Clomipramine \[N06AA04\]\
                                                         Desipramine \[N06AA01\]\
                                                         Doxepin \[N06AA12\]\
                                                         Dosulepin \[N06AA16\]\
                                                         Imipramine \[N06AA02\]\
                                                         Maprotiline \[N06AA21\]\
                                                         Nortriptyline \[N06AA10\]\
                                                         Reboxetine \[N06AX18\]\
                                                         Tranylcypromine \[N06AF04\]\
                                                         Trimipramine \[N06AA06\]\
                                                         **Cardiac glycosides \[C01A\]**\
                                                         Digoxin \[C01AA05\]

  Postural and orthostatic hypotension                   **Antidepressants \[N06A\]**\
                                                         Amitriptyline \[N06AA09\]\
                                                         Amoxapine \[N06AA17\]\
                                                         Clomipramine \[N06AA04\]\
                                                         Desipramine \[N06AA01\]\
                                                         Doxepin \[N06AA12\]\
                                                         Dosulepin \[N06AA16\]\
                                                         Imipramine \[N06AA02\]\
                                                         Maprotiline \[N06AA21\]\
                                                         Nortriptyline \[N06AA10\]\
                                                         Reboxetine \[N06AX18\]\
                                                         Tranylcypromine \[N06AF04\]\
                                                         Trimipramine \[N06AA06\]\
                                                         **Antiadrenergic agents (centrally acting) \[C02A\]**\
                                                         Clonidine \[C02AC01\]\
                                                         Guanabenz\*\
                                                         Guanfacine \[C02AC02\]\
                                                         Methyldopa \[C02AB\]\
                                                         Moxonidine \[C02AC05\]\
                                                         Reserpine \[C02AA02\]\
                                                         Rilmenidine \[C02AC06\]\
                                                         **Antiadrenergic agents (peripherally acting) \[C02C\]**\
                                                         Doxazosin \[C02CA04\]\
                                                         Guanethidine \[C02CC02\]\
                                                         Prazosin \[C02CA01\]\
                                                         Urapidil \[C02CA06\]\
                                                         **Anticholinergic agents \[N04A\]**\
                                                         Benzatropine \[N04AC01\]\
                                                         Biperiden \[N04AA02\]\
                                                         Orphenadrine \[N04AB02\]\
                                                         Trihexyphenidyl \[N04AA01\]\
                                                         Tropatepine \[N04AA12\]\
                                                         **Antipsychotics \[N05A\]**\
                                                         Clozapine \[N05AH02\]\
                                                         Chlorpromazine \[N05AA01\]\
                                                         Flupentixol \[N05AF01\]\
                                                         Prochlorperazine \[N05AB04\]\
                                                         Sertindole \[N05AE03\]\
                                                         Trifluoperazine \[N05AB \[06\]\
                                                         Ziprasidone \[N05AE04\]\
                                                         Zuclopenthixol \[N05AF05\]\
                                                         **Antithrombotic agents \[B01A\]**\
                                                         Dipyridamole \[B01AC07\]\
                                                         **Agents acting on arteriolar smooth muscle \[C02D\]**\
                                                         Hydralazine \[C02DB02\]\
                                                         **Capillary stabilizing agents \[C05C\]**\
                                                         Hidrosmin \[C05CA05\]\
                                                         **Dopaminergic agents \[N04B\]**\
                                                         Cabergoline \[N04BC06\]\
                                                         Pergolide \[N04BC02\]\
                                                         Piribedil \[N04BC08\]\
                                                         Pramipexole \[N04BC05\]\
                                                         Ropinirole \[N04BC04\]\
                                                         Rotigotine \[N04BC09\]\
                                                         Selegiline \[N04BD01\]\
                                                         **Drugs used in benign prostatic hypertrophy \[G04C\]**\
                                                         Terazosin \[G04CA03\]\
                                                         **Hypnotics and sedatives \[N05C\]**\
                                                         Clomethiazole \[N05CM02\]\
                                                         Propiomazine \[N05CM06\]\
                                                         **Muscle relaxants (centrally acting) \[M03B\]**\
                                                         Baclofen \[M03BX01\]\
                                                         Carisoprodol \[M03BA02\]\
                                                         Cyclobenzaprine \[M03BX08\]\
                                                         Methocarbamol \[M03BA03\]\
                                                         Tetrazepam \[M03BX07\]\
                                                         Tizanidine \[M03BX02\]\
                                                         **Natural products** Escin **Peripheral vasodilators \[C04A\]**\
                                                         Buflomedil \[C04AX20\]\
                                                         Cyclandelate \[C04AX01\]\
                                                         Dihydroergocristine \[C04AE04\]\
                                                         Dihydroergotoxine Moxisylyte \[C04AX10\]\
                                                         Naftidrofuryl \[C04AX21\]\
                                                         Nicergoline \[C04AE02\]\
                                                         Pentoxifylline \[C04AD03\]\
                                                         Vinburnine \[C04AX17\]\
                                                         Vincamine \[C04AX07\]\
                                                         **Psychostimulants \[N06B\]**\
                                                         Piracetam \[N06BX03\]\
                                                         **Selective calcium channel blockers with mainly vascular effects \[C08C\]**\
                                                         Nifedipine \[C08CA05\]

  Cardiac arrhythmias                                    **Antidepressants \[N06A\]**\
                                                         Amitriptyline \[N06AA09\]\
                                                         Amoxapine \[N06AA17\]\
                                                         Clomipramine \[N06AA04\]\
                                                         Desipramine \[N06AA01\]\
                                                         Doxepin \[N06AA12\]\
                                                         Dosulepin \[N06AA16\]\
                                                         Imipramine \[N06AA02\]\
                                                         Maprotiline \[N06AA21\]\
                                                         Nortriptyline \[N06AA10\]\
                                                         Reboxetine \[N06AX18\]\
                                                         Tranylcypromine \[N06AF04\]\
                                                         Trimipramine \[N06AA06\]\
                                                         **Antiarrhythmics (Class I and III) \[C01B\]**\
                                                         Amiodarone \[C01BD01\]\
                                                         Dronedarone \[C01BD07\]\
                                                         Flecainide \[C01BC04\]\
                                                         Propafenone \[C01BC03\]\
                                                         **Beta blocking agents \[C07A\]**\
                                                         Sotalol \[C07AA07\]\
                                                         **Other cardiac preparations \[C01E\]**\
                                                         Ivabradine \[C01EB17\]\
                                                         **Other systemic drugs for obstructive airway diseases \[R03D\]**\
                                                         Theophylline \[R03DA04\]\
                                                         **Quinolone antibacterials \[J01M\]**\
                                                         Ofloxacin \[J01MA01\]\
                                                         **Thyroid preparations \[H03A\]**\
                                                         Levothyroxine \[H03AA01\]

  Bradycardia                                            **Antiadrenergic agents (centrally acting) \[C02A\]**\
                                                         Clonidine \[C02AC01\]\
                                                         Guanabenz\*\
                                                         Guanfacine \[C02AC02\]\
                                                         Methyldopa \[C02AB\]\
                                                         Moxonidine \[C02AC05\]\
                                                         Reserpine \[C02AA02\]\
                                                         Rilmenidine \[C02AC06\]\
                                                         **Anti-epileptics \[N03A\]**\
                                                         Carbamazepine \[N03AF01\]\
                                                         **Selective calcium channel blockers with direct cardiac effects \[C08D\]**\
                                                         Diltiazem \[C08DB01\]\
                                                         Verapamil \[C08DA01\]

  QT prolongation                                        **Antiarrhythmics (Class I and III) \[C01B\]**\
                                                         Amiodarone \[C01BD01\]\
                                                         Dronedarone \[C01BD07\]\
                                                         Flecainide \[C01BC04\]\
                                                         Propafenone \[C01BC03\]\
                                                         **Antihistamines for systemic use \[R06A\]**\
                                                         Chlorpheniramine \[R06AB02\]\
                                                         Clemastine \[R06AA04\]\
                                                         Dimetindene \[R06AB03\]\
                                                         Doxylamine \[R06AA09\]\
                                                         Triprolidine \[R06AX07\]\
                                                         **Antipsychotics \[N05A\]**\
                                                         Clozapine \[N05AH02\]\
                                                         Chlorpromazine \[N05AA01\]\
                                                         Flupentixol \[N05AF01\]\
                                                         Prochlorperazine \[N05AB04\]\
                                                         Sertindole \[N05AE03\]\
                                                         Trifluoperazine \[N05AB06\]\
                                                         Ziprasidone \[N05AE04\]\
                                                         Zuclopenthixol \[N05AF05\]\
                                                         **Anxiolytics \[N05B\]**\
                                                         Hydroxyzine \[N05BB01\]\
                                                         **Urologicals \[G04B\]**\
                                                         Oxybutynin (short-acting) \[G04BD04\]\
                                                         Oxybutynin (long-acting) \[G04BD04\]\
                                                         Solifenacin \[G04BD08\]\
                                                         Tolterodine (short-acting) \[G04BD07\]\
                                                         Tolterodine (long-acting) \[G04BD07\]
  ---------------------------------------------------------------------------------------------------------------------------------------

**Note:**

No ATC code available.

**Abbreviation:** NSAIDs, nonsteroidal anti-inflammatory drugs.
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###### 

Sociodemographic and clinical features of the Portuguese elderly sample

  Characteristics                                        Total (n=680)   Long-term care facilities (n=137)   Ambulatory setting (n=543)   *P*-value
  ------------------------------------------------------ --------------- ----------------------------------- ---------------------------- ----------------------------------------------------
                                                                                                                                          
  Age -- n (%), years                                                                                                                     \<0.0001[a](#tfn1-cia-14-535){ref-type="table-fn"}
   65--74                                                251 (36.9)      9 (6.6)                             242 (44.6)                   
   75--84                                                255 (37.5)      46 (33.6)                           209 (38.5)                   
   ≥85                                                   173 (25.4)      81 (59.1)                           92 (16.9)                    
                                                                                                                                          
  Age -- mean ± SD, years                                78.4±8.1        85.4±6.5                            76.7±7.5                     \<0.0001[a](#tfn1-cia-14-535){ref-type="table-fn"}
                                                                                                                                          
  Male sex -- n (%)                                      252 (37.1)      41 (29.9)                           211 (38.9)                   0.053
                                                                                                                                          
  Comorbidities -- mean ± SD                             3.7±1.8         4.7±2.3                             3.5±1.6                      \<0.0001[a](#tfn1-cia-14-535){ref-type="table-fn"}
                                                                                                                                          
  Comorbidities -- n (%)                                                                                                                  \<0.0001[a](#tfn1-cia-14-535){ref-type="table-fn"}
   1--3                                                  321 (47.2)      46 (33.6)                           275 (50.6)                   
   4                                                     176 (25.9)      30 (21.9)                           146 (26.9)                   
   5                                                     86 (12.6)       16 (11.7)                           70 (12.9)                    
   6                                                     46 (6.8)        12 (8.8)                            34 (6.3)                     
   7                                                     18 (2.6)        12 (8.8)                            6 (1.1)                      
   8                                                     18 (2.6)        9 (6.6)                             9 (1.7)                      
   ≥9                                                    15 (2.2)        12 (8.8)                            3 (0.6)                      
                                                                                                                                          
  Previous history of cardiovascular diseases -- n (%)   521 (76.6)      110 (80.3)                          411 (75.7)                   0.256
                                                                                                                                          
  Dementia -- n (%)                                      73 (10.7)       25 (18.2)                           48 (8.8)                     0.001[a](#tfn1-cia-14-535){ref-type="table-fn"}
                                                                                                                                          
  Polypharmacy -- n (%)                                  509 (74.9)      135 (98.5)                          373 (68.7)                   \<0.0001[a](#tfn1-cia-14-535){ref-type="table-fn"}
                                                                                                                                          
  Number of medications -- mean ± SD                     7.5±4.2         10.4±3.9                            6.8±4.0                      \<0.0001[a](#tfn1-cia-14-535){ref-type="table-fn"}
                                                                                                                                          
  Number of medications -- n (%)                                                                                                          \<0.0001[a](#tfn1-cia-14-535){ref-type="table-fn"}
   1--5                                                  240 (35.3)      8 (5.8)                             232 (42.7)                   
   6--7                                                  133 (19.6)      22 (16.0)                           111 (20.4)                   
   8--9                                                  112 (16.5)      35 (25.5)                           77 (14.2)                    
   10--11                                                87 (12.8)       27 (19.7)                           60 (11.0)                    
   12--13                                                52 (7.6)        24 (17.5)                           28 (5.2)                     
   14--15                                                23 (3.4)        8 (5.8)                             15 (2.8)                     
   ≥16                                                   33 (4.9)        13 (9.5)                            20 (3.7)                     

**Note:**

Statistically significant (*P*\<0.05).

###### 

Number of patients using PIMs associated with risk of CCVAE or MACCE

  Type of PIMs                                                                  Total        Long-term care facilities   Ambulatory setting   *P*-value
  ----------------------------------------------------------------------------- ------------ --------------------------- -------------------- ----------------------------------------------------
  PIMs with risk of CCVAE                                                                                                                     
   Total number of PIMs -- n (%)                                                682 (13.3)   185 (12.9)                  497 (13.5)           --
   Mean number of PIMs/patient -- mean ± SD                                     1.7±1.0      1.7±0.9                     1.7±1.0              0.409
   1 PIM -- n (%)                                                               223 (55.2)   54 (50.5)                   169 (56.9)           0.409
   2 PIMs                                                                       113 (28.0)   36 (33.6)                   77 (25.9)            
   3 PIMs                                                                       49 (12.1)    12 (11.2)                   37 (12.5)            
   4 PIMs                                                                       12 (3.0)     3 (2.8)                     9 (3.0)              
   ≥5 PIMs                                                                      7 (1.7)      2 (1.9)                     5 (1.7)              
   Total number of patients taking PIMs -- n (%)                                404 (59.4)   107 (78.1)                  297 (54.7)           \<0.0001[a](#tfn2-cia-14-535){ref-type="table-fn"}
   Total number of patients taking PIMs with previous history of CVD -- n (%)   322 (47.4)   87 (63.5)                   253 (46.6)           \<0.0001[a](#tfn2-cia-14-535){ref-type="table-fn"}
  PIMs with risk of MACCE                                                                                                                     
   Total number of PIMs -- n (%)                                                378 (7.4)    100 (7.0)                   278 (7.6)            --
   Mean number of PIMs -- mean ± SD                                             1.4±0.8      1.4±0.8                     1.4±0.8              0.336
   1 PIM -- n (%)                                                               182 (68.9)   53 (74.6)                   129 (66.8)           0.336
   2 PIMs                                                                       62 (23.5)    11 (15.5)                   51 (26.4)            
   3 PIMs                                                                       11 (4.2)     4 (5.6)                     7 (3.6)              
   4 PIMs                                                                       6 (2.3)      2 (2.8)                     4 (2.1)              
   ≥5 PIMs                                                                      3 (1.1)      1 (1.4)                     2 (1.0)              
   Total number of patients taking PIMs -- n (%)                                264 (38.8)   71 (51.8)                   193 (35.5)           \<0.0001[a](#tfn2-cia-14-535){ref-type="table-fn"}
   Total number of patients taking PIMs with previous history of CVD -- n (%)   202 (29.7)   55 (40.1)                   147 (27.1)           0.003[a](#tfn2-cia-14-535){ref-type="table-fn"}

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviations:** CCVAE, cardiac and cerebrovascular adverse event; CVD, cardiovascular disease; MACCE, major adverse cardiac and cerebrovascular events; PIMs, potentially inappropriate medications.

###### 

Most commonly prescribed pharmacotherapeutic groups associated with risk of CCVAEs in both settings

  Pharmacotherapeutic groups with risk of CCVAE -- n (%)            ATC code   Total        Long-term care facilities   Ambulatory setting
  ----------------------------------------------------------------- ---------- ------------ --------------------------- --------------------
  Antiadrenergic agents (centrally acting)                          C02A       12 (1.8)     0 (0.0)                     12 (2.5)
  Antiarrhythmics (Class I and III)                                 C01B       19 (2.8)     5 (2.8)                     14 (2.9)
  Antidepressants                                                   N06A       57 (8.5)     19 (10.5)                   38 (7.8)
  Antipsychotics                                                    N05A       118 (17.6)   70 (38.7)                   48 (9.9)
  Anxiolytics                                                       N05B       13 (1.9)     5 (2.8)                     8 (1.6)
  Beta blocking agents                                              C07A       5 (0.7)      0 (0.0)                     5 (1.0)
  Capillary stabilizing agents                                      C05C       8 (1.2)      2 (1.1)                     6 (1.2)
  Cardiac glycosides                                                C01A       18 (2.7)     12 (6.6)                    6 (1.2)
  Dopaminergic agents                                               N04B       9 (1.3)      6 (3.3)                     3 (0.6)
  Drugs affecting bone structure and mineralization                 M05B       4 (0.6)      1 (0.6)                     3 (0.6)
  Hormones and related agents                                       L02A       13 (1.9)     0 (0.0)                     13 (2.7)
  Muscle relaxants (centrally acting)                               M03B       13 (1.9)     3 (1.7)                     10 (2.1)
  Natural products                                                  --         25 (3.7)     6 (3.3)                     19 (3.9)
  Nonsteroidal anti-inflammatory drugs                              M01A       199 (29.7)   23 (12.7)                   176 (36.2)
  Other cardiac preparations                                        C01E       4 (0.6)      1 (0.6)                     3 (0.6)
  Other systemic drugs for obstructive airway diseases              R03D       7 (1.0)      0 (0.0)                     7 (1.4)
  Peripheral vasodilators                                           C04A       33 (4.9)     8 (4.4)                     25 (5.1)
  Psychostimulants                                                  N06B       6 (0.9)      1 (0.6)                     5 (1.0)
  Selective calcium channel blockers with direct cardiac effects    C08D       9 (1.3)      0 (0.0)                     9 (1.9)
  Selective calcium channel blockers with mainly vascular effects   C08C       24 (3.6)     3 (1.7)                     21 (4.3)
  Thyroid preparations                                              H03A       70 (10.4)    16 (8.8)                    54 (11.1)
  Urologicals                                                       G04B       4 (0.6)      0 (0.0)                     4 (0.8)

**Abbreviation:** CCVAEs, cardiac and cerebrovascular adverse events.

###### 

Most commonly prescribed PIMs associated with risk of MACCE in both settings

  PIMs associated with risk of MACCE -- n (%)   Total        Long-term care facilities   Ambulatory setting
  --------------------------------------------- ------------ --------------------------- --------------------
                                                                                         
  Antidepressants                               21 (5.6)     2 (2.0)                     19 (6.9)
   Venlafaxine                                  21 (100.0)   2 (100.0)                   19 (100.0)
                                                                                         
  Antipsychotics                                118 (31.5)   70 (71.4)                   47 (17.2)
   Amisulpride                                  7 (5.9)      0 (0.0)                     7 (14.9)
   Aripiprazole                                 2 (1.7)      0 (0.0)                     2 (4.4)
   Cyamemazine                                  13 (11.0)    11 (15.7)                   2 (4.4)
   Chlorpromazine                               2 (1.7)      2 (2.9)                     0 (0.0)
   Clozapine                                    7 (5.9)      3 (4.3)                     4 (8.5)
   Fluphenazine                                 1 (0.8)      1 (1.4)                     0 (0.0)
   Haloperidol                                  5 (4.2)      5 (7.1)                     0 (0.0)
   Levomepromazine                              1 (0.8)      0 (0.0)                     1 (2.2)
   Melperone                                    19 (16.1)    17 (24.3)                   2 (4.4)
   Olanzapine                                   6 (5.0)      4 (5.7)                     2 (4.4)
   Paliperidone                                 1 (0.8)      0 (0.0)                     1 (2.2)
   Quetiapine                                   48 (40.7)    26 (37.1)                   22 (46.8)
   Risperidone                                  5 (4.2)      0 (0.0)                     5 (10.6)
   Tiapride                                     1 (0.8)      1 (1.4)                     0 (0.0)
                                                                                         
  Hormones and related agents                   13 (3.5)     0 (0.0)                     13 (4.7)
   Estrogen                                     13 (100.0)   0 (0.0)                     13 (100.0)
                                                                                         
  Nonsteroidal anti-inflammatory drugs          199 (53.1)   23 (23.5)                   175 (63.9)
   Aceclofenac                                  10 (5.0)     4 (17.4)                    6 (3.4)
   Acemetacin                                   1 (0.5)      1 (4.3)                     0 (0.0)
   Aspirin (500 mg)                             7 (3.5)      0 (0.0)                     7 (4.0)
   Celecoxib                                    11 (5.5)     8 (34.8)                    3 (1.7)
   Diclofenac                                   43 (21.6)    3 (13.0)                    40 (22.9)
   Etodolac                                     5 (2.5)      1 (4.3)                     4 (2.4)
   Etoricoxib                                   20 (10.0)    1 (4.3)                     19 (10.9)
   Flurbiprofen                                 15 (7.5)     0 (0.0)                     15 (8.6)
   Ibuprofen                                    46 (23.1)    3 (13.0)                    43 (24.6)
   Indometacin                                  2 (1.0)      0 (0.0)                     2 (1.2)
   Mefenamic acid                               1 (0.5)      0 (0.0)                     1 (0.6)
   Naproxen                                     20 (10.0)    2 (8.6)                     18 (10.3)
   Nimesulide                                   16 (8.0)     0 (0.0)                     16 (9.1)
   Piroxicam                                    2 (1.0)      0 (0.0)                     2 (1.2)
                                                                                         
  Selective CCB with mainly vascular effects    24 (6.4)     3 (3.1)                     21 (7.7)
   Nifedipine                                   24 (100.0)   3 (100.0)                   21 (100.0)

**Abbreviations:** MACCE, major adverse cardiac and cerebrovascular events; PIMs, potentially inappropriate medications; CCB, calcium channel blockers.
